---
title: "VK2735 in Chronic weight management: Dosage"
description: "Formulary evidence on VK2735 in Chronic weight management: Dosage. Topics: Subcutaneous formulation: maintenance doses in the VANQUISH phase 3 trials, Subcutaneous formulation: titration schedule in the VANQUISH phase 3 trials, Subcutaneous formulation: rationale for the 1.25 mg starting dose, Subcutaneous formulation: doses and titration in the phase 2 trial, and 9 further topics. 13 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/dosage"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Proposed labeled dose, titration, and dose modification

No evidence found.

<a id="topic-2.1.2.10.1-2"></a>

### Subcutaneous formulation: maintenance doses in the VANQUISH phase 3 trials

> “Participants in each trial have been randomized to weekly doses of 7.5 mg, 12.5 mg, 17.5 mg, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.10.1-3"></a>

### Subcutaneous formulation: titration schedule in the VANQUISH phase 3 trials

> “What we did in the phase III is we've started people at 1.25 mgs for two weeks, then go up to 2.5 mgs for four, and you go up in 2.5 mg increments in four-week blocks.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

> “So two weeks at 1.25 and then four weeks at 2.5, four weeks at 5, and so on up to 17.5. And when you get to 17.5, that's when the 52-week stable dose window starts.”

Source: [Viking Therapeutics J.P. Morgan conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/537697-44th-annual-j-p-morgan-healthcare-conference/)

<a id="topic-2.1.2.10.1-4"></a>

### Subcutaneous formulation: rationale for the 1.25 mg starting dose

> “Given that the 5 mg dose had a higher GI TEAE rate than the 10 mg dose, there does not seem to be a dose‐dependent increase in GI TEAEs if a 2.5 mg starting dose is used at the beginning of the titration phase. The clear benefit of starting below 5.0 mg and titrating up has informed the phase 3 trial design to further improve tolerability.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

> “When we think about GI tolerability, a lot of that is tied to the initial exposures and then the overall exposure as well. What is the dose level? Which is one of the reasons we started at 1.25 mgs in the VANQUISH studies.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.1.2.10.1-5"></a>

### Subcutaneous formulation: doses and titration in the phase 2 trial

> “Participants who met eligibility criteria were randomized to one of four VK2735 weekly subcutaneous injection treatment groups (2.5, 5.0, 10, or 15 mg) or the matched placebo injection group in a 1:1:1:1:1 ratio on day 1”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

> “2.5 mg cohort = 2.5 x 13 weeks”
> “5.0 mg cohort = 2.5 mg x 3 wks, 5 mg x 10 wks”
> “10.0 mg cohort = 2.5 mg x 3 wks, 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 4 wks”
> “15.0 mg cohort = 5 mg x 3 wks, 7.5 mg x 3 wks, 10 mg x 3 wks, 15 mg x 4 wks”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.10.1-6"></a>

### Subcutaneous formulation: doses in the phase 1 single and multiple ascending dose study

> “Well tolerated up to 7.5 mg single doses”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

> “Subjects received escalating weekly doses of 1.5 mg, 3.0 mg, 5.0 mg, 5.0 mg.”
> “The company believes tolerability data from this study indicate that higher doses may be achieved with longer titration windows.”

Source: [Viking Therapeutics phase 1 results release (2023)](https://ir.vikingtherapeutics.com/2023-03-28-Viking-Therapeutics-Announces-Results-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735)

<a id="topic-2.1.2.10.1-7"></a>

### Subcutaneous formulation: induction doses and two-week titration in the maintenance study

> “Starting in Week 3, VK2735 doses were escalated every two weeks until final doses of 15.0 mg, 17.5 mg, 20.0 mg, or 22.5 mg were achieved.”
> “Subjects treated with VK2735 were titrated to final doses as indicated: Week 1 = 1.25 mg; Week 2 = 2.5 mg; Week 3-4 = 5.0 mg; Week 5-6 = 7.5 mg; Week 7-8 = 10.0 mg; Week 9-10 = 12.5 mg; Week 11-12 = 15.0 mg; Week 13-14 = 17.5 mg; Week 15-16 = 20.0 mg; Week 17 = 22.5 mg.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-2.1.2.10.1-8"></a>

### Subcutaneous formulation: every-other-week and monthly maintenance regimens

> “At Week 21 subjects were transitioned to maintenance dosing as indicated and treated for 12 weeks: 17.5 mg weekly to 5.0 mg QOW; 15 mg weekly to 7.5 mg QOW; 17.5 mg weekly to 10 mg QOW.”
> “During the maintenance dosing period, participants were randomized to a range of monthly (every four weeks) and every-other-week dosing regimens to evaluate the effect of less frequent dosing on weight maintenance.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-2.1.2.10.1-9"></a>

### Subcutaneous formulation: less frequent regimens in the VANQUISH-1 extension

> “In addition, the VANQUISH-1 extension study will include certain less-frequent dosing regimens, including every-other-week and monthly administration.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.10.1-10"></a>

### Subcutaneous induction followed by oral or subcutaneous maintenance

> “As in Part 1, all participants will receive initial weekly subcutaneous doses of VK2735 for 21 weeks. Following Week 21, participants will transition to a range of VK2735 maintenance dosing options including daily oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-2.1.2.10.1-11"></a>

### Oral formulation: doses in the SUNRISE phase 3 trials

> “Participants in both trials will be randomly assigned to one of four treatment groups receiving once-daily VK2735 doses of 27.5 mg, 35 mg, 55 mg, or placebo.”

Source: [Viking Therapeutics SUNRISE initiation release (2026)](https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity)

<a id="topic-2.1.2.10.1-12"></a>

### Oral formulation: doses and titration in the phase 2 trial

> “Titration scheme: 15 mg cohort = 15 mg x 13 weeks; 30 mg cohort = 30 mg x 13 wks; 60 mg cohort = 30 mg x 2 wks, 60 mg x 11 wks; 90 mg cohort = 30 mg x 2 wks, 60 mg x 2 wks, 90 mg x 9 wks; 120 mg cohort = 30 mg x 2 wks, 60 mg x 2 wks, 90 mg x 2 wks, 120 mg x 7 wks.”
> “Potential Future Dose Range ~20 mg to ~60 mg”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.10.1-13"></a>

### Oral formulation: down-titration from 90 mg to 30 mg daily in the phase 2 maintenance cohort

> “In this treatment group, participants were rapidly titrated to 90 mg daily doses. After 4 weeks of daily dosing at 90 mg, participants were down-titrated to 30 mg daily doses and maintained at 30 mg daily for 7 weeks.”

Source: [Viking Therapeutics VENTURE-Oral topline release (2025)](https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-with-Obesity)

<a id="topic-2.1.2.10.1-14"></a>

### Oral formulation: doses and titration in the phase 1 multiple ascending dose study

> “Subjects treated with VK2735 were titrated to final doses as: 2.5 mg cohort = 2.5 daily x 4 weeks; 5 mg cohort = 2.5mg daily x 1 wk, 5 mg daily x 3 wks; 10 mg cohort = 5 mg daily x 1 wk, 10 mg daily x 3 wks; 20 mg cohort = 15 mg daily x 1 wk, 20 mg daily x 3 wks; 40 mg cohort = 20 mg daily x 1 wk, 40 mg daily x 3 wks; 60 mg cohort = 40 mg daily x 1 wk, 60 mg daily x 3 wks; 80 mg A = 60 mg daily x 1 wk, 80 mg daily x 3 wks; 80 mg B = 60 mg daily x 1 wk, 80 mg daily x 1 wk, 80 mg QoD x 2 wks; 100 mg cohort = 80 mg daily x 1 wk, 100 mg daily x 3 wks.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
